日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

奥洛莫拉西布(一种新一代 KRAS G12C 抑制剂)在 KRAS G12C 突变型晚期实体瘤中的泛肿瘤活性:一项首次人体研究

Murciano-Goroff, Yonina R; Hollebecque, Antoine; Heist, Rebecca S; Cassier, Philippe A; Han, Ji-Youn; Kim, So Yeon; Sabari, Joshua K; Tosi, Diego; Sacher, Adrian; Burns, Timothy F; Shimizu, Toshio; Reddy Ammakkanavar, Natraj; Spira, Alexander; Gomez-Roca, Carlos; Patnaik, Amita; Cosman, Rasha; Bodor, J Nicholas; Nagasaka, Misako; You, Arthur Xintian; McNeely, Samuel C; Peter, Raimund; Fink, Aaron; Chen, Aaron; Oxnard, Geoffrey R; Willard, Melinda D; Kuboki, Yasutoshi; Koyama, Takafumi

A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer.

一项 I 期临床试验,研究肝动脉内递送 TG6002 与口服 5-氟胞胞嘧啶联合治疗以肝脏转移为主的结直肠癌患者的疗效

West Emma J, Sadoun Alain, Bendjama Kaidre, Erbs Philippe, Smolenschi Cristina, Cassier Philippe A, de Baere Thierry, Sainte-Croix Sophie, Brandely Maud, Melcher Alan A, Ismail Fay, Scott Karen J, Bennett Angela, Banks Emma, Gasior Ewa, Kent Sarah, Kurzawa Marta, Hammond Christopher, Patel Jai V, Collinson Fiona J, Twelves Chris, Anthoney D Alan, Swinson Dan, Samson Adel

Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort

乐伐替尼联合帕博利珠单抗治疗既往接受过治疗的特定实体瘤患者:来自 LEAP-005 II 期研究复发性胶质母细胞瘤队列的结果

Rha, Sun Young; Castanon, Eduardo; Gill, Sanjeev; Senellart, Helene; Lopez, Juanita; Márquez-Rodas, Iván; Victoria, Iván; Kim, Tae Min; Lwin, Zarnie; Burger, Michael C; Simonelli, Matteo; Cassier, Philippe A; Hendifar, Andrew E; Ascierto, Paolo A; Dutcus, Corina; Okpara, Chinyere E; Ghori, Razi; Jin, Fan; Groisberg, Roman; Villanueva, Luis

Barriers to publishing early phase clinical trials: the oncologists' perspective

早期临床试验发表的障碍:肿瘤学家的视角

Lucassen, Merel J J; Bergmann, Pedro; Husson, Olga; Banerji, Udai; Basu, Bristi; Melero, Ignacio; Calvo, Emiliano; Cassier, Philippe A; Drilon, Alexander; Fong, Peter C; Garralda, Elena; Joshua, Anthony M; Lin, Chia-Chi; Lopez, Juanita; Moreno, Victor; Minchom, Anna; Plummer, Ruth; Postel-Vinay, Sophie; Spreafico, Anna; Shimizu, Toshio; Yap, Timothy A; Yap, Christina; De Bono, Johann S; Steeghs, Neeltje

Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

TRK-950(一种特异性针对 CAPRIN-1 的 IgG1 抗体)在晚期实体瘤患者中的 I 期首次人体研究

Cassier, Philippe A; Borad, Mitesh J; Sharma, Sunil; Dubois, Bertrand; Caux, Christophe; Okano, Fumiyoshi; Von Hoff, Daniel D; Blay, Jean-Yves

Selpercatinib in the treatment of thyroid cancer

塞帕替尼在甲状腺癌治疗中的应用

Gauduchon, Thibault; Varnier, Romain; Cassier, Philippe A

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001

Selpercatinib治疗RET激活型甲状腺癌患者的疗效持久性:LIBRETTO-001研究的长期安全性和有效性

Wirth, Lori J; Brose, Marcia S; Subbiah, Vivek; Worden, Francis; Solomon, Ben; Robinson, Bruce; Hadoux, Julien; Tomasini, Pascale; Weiler, Daniela; Deschler-Baier, Barbara; Tan, Daniel S W; Maeda, Patricia; Lin, Yan; Singh, Ravinder; Bayt, Theresa; Drilon, Alexander; Cassier, Philippe A

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

一项针对晚期实体恶性肿瘤患者的 II 期、多中心、开放标签研究,评估抗 LAG-3 抗体 ieramilimab 联合抗 PD-1 抗体 spartalizumab 的疗效。

Lin, Chia-Chi; Garralda, Elena; Schöffski, Patrick; Hong, David S; Siu, Lillian L; Martin, Miguel; Maur, Michela; Hui, Rina; Soo, Ross A; Chiu, Joanne; Zhang, Tian; Ma, Brigette; Kyi, Chrisann; Tan, Daniel Sw; Cassier, Philippe A; Sarantopoulos, John; Weickhardt, Andrew; Carvajal, Richard D; Spratlin, Jennifer; Esaki, Taito; Rolland, Fréderic; Akerley, Wallace; Deschler-Baier, Barbara; Rispoli, Lawrence; Samant, Tanay S; Chowdhury, Niladri Roy; Gusenleitner, Daniel; Kwak, Eunice L; Askoxylakis, Vasileios; De Braud, Filippo

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

FOENIX-CCA2 研究简明摘要:富巴替尼治疗晚期胆管癌

Goyal, Lipika; Meric-Bernstam, Funda; Hollebecque, Antoine; Valle, Juan W; Morizane, Chigusa; Karasic, Thomas B; Abrams, Thomas A; Furuse, Junji; Kelley, Robin Katie; Cassier, Philippe A; Klümpen, Heinz-Josef; Chang, Heung-Moon; Chen, Li-Tzong; Tabernero, Josep; Oh, Do-Youn; Mahipal, Amit; Moehler, Markus; Komatsu, Yoshito; Ahn, Daniel H; Epstein, Robert S; Halim, Abdel-Baset; Wacheck, Volker; He, Yaohua; Liu, Mei; Benhadji, Karim A; Bridgewater, John A

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

索拉非尼在分子分选癌症患者中的应用:MOST-Plus 索拉非尼队列的最终分析

Trédan, Olivier; Toulmonde, Maud; Le Tourneau, Christophe; Montane, Laure; Italiano, Antoine; Ray-Coquard, Isabelle; De La Fouchardière, Christelle; Bertucci, François; Gonçalves, Anthony; Gomez-Roca, Carlos; You, Benoit; Attignon, Valéry; Boyault, Sandrine; Cassier, Philippe A; Dufresne, Armelle; Tabone-Eglinger, Séverine; Viari, Alain; Sohier, Emilie; Kamal, Maud; Garin, Gwenaël; Blay, Jean-Yves; Pérol, David